BACKGROUNDNeutrophilic‐chronic myeloid leukemia (CML‐N) has been described as a CML variant associated both with a distinctive molecular defect of the Philadelphia chromosome and with a more benign clinical course than classic CML. The translocation (9;22) in CML‐N results in the transcription of an e19/a2 type BCR/ABL mRNA that codes for a 230‐kD BCR/ABL protein (p230). The indolence of the clinical course of patients with CML‐N has been disputed.METHODSThe objectives of this study were to quantify and correlate with clinical outcome the p230 mRNA and protein in patients with CML‐N, to describe six new patients and the follow‐up (with molecular analysis) of five previously reported patients with CML‐N, and to review characteristics of all patients with CML‐N and p230 BCR/ABL reported to date in the literature.RESULTSQuantitative polymerase chain reaction assays on specimens from the great majority of patients with CML‐N revealed minimal numbers of molecules of p230 BCR/ABL transcripts per total RNA. This also was associated with a lack of detectable p230 BCR/ABL protein in patient specimens, even in one patient who was followed for 16 years after diagnosis. This may explain the milder leukemic phenotype in most patients with CML‐N. A review of all 23 patients who had an e19/a2 type BCR/ABL translocation suggested that the low level of p230 BCR/ABL mRNA and the lack of detectable p230 BCR/ABL protein in patients with no additional cytogenetic abnormalities may predict their indolent clinical course.CONCLUSIONSPatients with p230 positive CML‐N have indolent course, probably as a result of low p230 mRNA and protein levels. This supports the need to conduct additional molecular studies, even if cytogenetic studies have revealed t(9;22), because of the prognostic importance of the molecular findings. Cancer 2002;94:2416–25. © 2002 American Cancer Society.DOI 10.1002/cncr.10490